A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. uri icon

authors

  • Ramalingam, Sendhilnathan
  • Daniel Parker, MD
  • Bain, James
  • Muehlbauer, Michael
  • Ilkayeva, Olga
  • Kraus, Virginia Byers
  • Huebner, Janet L
  • Spitzer, Thomas
  • Brown, Jami
  • Peled, Jonathan U
  • van den Brink, Marcel
  • Siamakpour-Reihani, Sharareh
  • Gomes, Antonio
  • Choi, Taewoong
  • Gasparetto, Cristina
  • Horwitz, Mitchell
  • Long, Gwynn
  • Lopez, Richard
  • Rizzieri, David
  • Sarantopoulos, Stefanie
  • Chao, Nelson
  • Anthony Sung, MD
  • Bohannan, Lauren
  • Ren, Yi
  • Sibley, Alexander
  • Sheng, Jeff
  • Ma, Li
  • Nixon, Andrew B
  • Lyu, Jing

publication date

  • January 1, 2021